MeiraGTx (NASDAQ:MGTX – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.
Several other brokerages have also recently weighed in on MGTX. Royal Bank Of Canada upped their price target on MeiraGTx from $26.00 to $27.00 and gave the stock an “outperform” rating in a research note on Friday, August 14th. The Goldman Sachs Group began coverage on MeiraGTx in a research report on Thursday, September 24th. They set a “neutral” rating and a $16.00 price objective for the company. Weiss Ratings raised MeiraGTx from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Finally, Zacks Research cut shares of MeiraGTx from a “strong-buy” rating to a “hold” rating in a report on Friday, September 11th. Five research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $24.00.
Read Our Latest Stock Analysis on MGTX
MeiraGTx Price Performance
MeiraGTx (NASDAQ:MGTX – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.03). The firm had revenue of $4.81 million during the quarter, compared to the consensus estimate of $6.95 million. MeiraGTx had a return on equity of 85.23% and a net margin of 19.46%. As a group, analysts forecast that MeiraGTx will post 0.32 earnings per share for the current fiscal year.
Insider Transactions at MeiraGTx
In related news, insider Stuart Naylor sold 27,659 shares of the company’s stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $10.64, for a total value of $294,291.76. Following the sale, the insider owned 613,187 shares in the company, valued at $6,524,309.68. This represents a 4.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Alexandria Forbes sold 62,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $13.86, for a total value of $859,320.00. Following the completion of the sale, the chief executive officer owned 1,325,695 shares in the company, valued at $18,374,132.70. The trade was a 4.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 145,659 shares of company stock valued at $1,710,812 in the last ninety days. 7.40% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On MeiraGTx
Several hedge funds have recently added to or reduced their stakes in MGTX. Tocqueville Asset Management L.P. increased its holdings in shares of MeiraGTx by 13.3% during the third quarter. Tocqueville Asset Management L.P. now owns 88,000 shares of the company’s stock valued at $968,000 after acquiring an additional 10,300 shares in the last quarter. Polymer Capital Management US LLC purchased a new position in shares of MeiraGTx in the 3rd quarter worth about $121,000. Meeder Asset Management Inc. purchased a new position in shares of MeiraGTx in the 3rd quarter worth about $52,000. Global Retirement Partners LLC bought a new position in MeiraGTx in the 3rd quarter worth about $34,000. Finally, Russell Investments Group Ltd. boosted its stake in MeiraGTx by 2.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 150,565 shares of the company’s stock worth $1,656,000 after purchasing an additional 3,236 shares in the last quarter. 67.48% of the stock is owned by institutional investors.
About MeiraGTx
MeiraGTx Holdings plc is a biotechnology company developing gene therapies for serious diseases with limited treatment options. Its research focuses on using adeno-associated virus (AAV) vectors to deliver genetic material to target cells, including in programs for inherited retinal diseases, neurological conditions and salivary gland dysfunction. The company also develops manufacturing capabilities and technologies intended to support the production of gene therapies. MeiraGTx was founded in 2015 and has operations in the United States and the United Kingdom.
See Also
- Five stocks we like better than MeiraGTx
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.
